InvestorWire NewsRoom

InvestorNewsBreak

InvestorNewsBreaks – Coherus BioSciences Inc. (NASDAQ: CHRS) Featured in Mizuho Securities Research Report
May 7, 2021

InvestorNewsBreaks – Coherus BioSciences Inc. (NASDAQ: CHRS) Featured in Mizuho Securities Research Report

Coherus BioSciences (NASDAQ: CHRS) was featured in a recent equity research report published by Mizuho Securities USA LLC. The report reads, “Udenyca’s alternative dosing formulations and tori clinical programs, among other topics, were discussed. Key tidbits below: Udenyca. Net Udenyca sales were $83MM in 1Q21 compared to $110MM in 4Q20, a ~25% qoq decrease that according to management was a result of: 1) Inventory changes (inventory business days are as follows: end of 3Q20 11 business days, end of 4Q20 21 business days, end of 1Q21 12 business days), and by our math, each business day is worth $1.5MM; and 2) Pricing dynamics (AMGN’s Neulasta currently has the lowest ASP in all the pegfilgrastim market).”

To request access to the full report, visit https://ibn.fm/1II45

About Coherus BioSciences Inc.

Coherus is a commercial stage biopharmaceutical company with the mission to increase access to cost-effective medicines that can have a major impact on patients’ lives and to deliver significant savings to the health care system. Coherus’ strategy is to build a leading immuno-oncology franchise funded with cash generated by its commercial biosimilar business. Coherus markets UDENYCA(R) (pegfilgrastim-cbqv) in the United States and through 2023 expects to launch toripalimab, an anti-PD-1 antibody, as well as biosimilars of Lucentis(R), Humira(R), and Avastin(R), if approved. For more information, visit the company’s website at www.Coherus.com.

About InvestorWire

InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent. We offer UNLIMITED Words on all domestic releases. While other wire services may provide a basic review of your release, InvestorWire helps you put your best foot forward with complimentary Press Release Enhancement.

With our competitors, the work is done the second your release crosses the wire. Not with InvestorWire. We include follow-up coverage of every release by leveraging the ever-expanding audiences of the 50+ brands that make up the InvestorBrandNetwork.

Get more out of your next press release with InvestorWire. It’s unlike anything you’ve seen before.

For more information, please visit https://www.InvestorWire.com

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer

InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office
www.InvestorWire.com
[email protected]

InvestorWire is part of the InvestorBrandNetwork.

Recent NewsBreaks

NewsBreaks Categories

Get Started with InvestorWire

To distribute a release in the next 24 hours. Contact our client services team.

(310) 299-1717

Distribute a press release. Submit your release to get started.

Submit Press Release

Set up a Live demonstration. Schedule a date and time that works for you.

Schedule a LIVE Demo

Press Distribution

Explore Press Distribution Solutions

All releases include an unlimited word count* with full wire-grade syndication, our press release enhancement service, and a follow-up InvestorNewsBreak article distributed to thousands of editorial syndication partners.

Discover Add-on Solutions

Increase the impact of your achievements by adding these exclusive solutions from InvestorWire, delivered in conjunction with the InvestorBrandNetwork (IBN).